866-997-4948(US-Canada Toll Free)

Primary Biliary Cholangitis (Primary Biliary Cirrhosis)-Pipeline Review, H2 2019

Published By :

Global Markets Direct

Published Date : Aug 2019

Category :

Pharmaceutical

No. of Pages : 150 Pages

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cholangitis - Pipeline Review, H2 2019, provides an overview of the Primary Biliary Cholangitis (Gastrointestinal) pipeline landscape.

Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cholangitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Primary Biliary Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Biliary Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 2, 11, 3, 1, 1 and 3 respectively.

Primary Biliary Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cholangitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Primary Biliary Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Biliary Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Biliary Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cholangitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cholangitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Biliary Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Overview
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Companies Involved in Therapeutics Development
Albireo Pharma Inc
Allergan Plc
Biocad
Cadila Healthcare Ltd
Calliditas Therapeutics AB
CymaBay Therapeutics Inc
Dr. Falk Pharma GmbH
Eli Lilly and Co
Enanta Pharmaceuticals Inc
Genfit SA
GenKyoTex SA
Gilead Sciences Inc
Kowa Co Ltd
NGM Biopharmaceuticals Inc
Novartis AG
Suzhou Zelgen Biopharmaceutical Co Ltd
Tiziana Life Sciences Plc
Virobay Inc
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Drug Profiles
ABC-08 - Drug Profile
baricitinib - Drug Profile
bezafibrate SR - Drug Profile
budesonide - Drug Profile
Cilofexor - Drug Profile
EDP-305 - Drug Profile
elafibranor - Drug Profile
foralumab - Drug Profile
netakimab - Drug Profile
NGM-282 - Drug Profile
odevixibat - Drug Profile
pemafibrate - Drug Profile
PRI-724 - Drug Profile
saroglitazar - Drug Profile
seladelpar lysine - Drug Profile
setanaxib - Drug Profile
TQA-3526 - Drug Profile
tropifexor - Drug Profile
ursodiol - Drug Profile
VBY-825 - Drug Profile
ZG-5266 - Drug Profile
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Dormant Projects
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Discontinued Products
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Albireo Pharma Inc, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Allergan Plc, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Biocad, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Cadila Healthcare Ltd, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Calliditas Therapeutics AB, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by CymaBay Therapeutics Inc, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Dr. Falk Pharma GmbH, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Eli Lilly and Co, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Enanta Pharmaceuticals Inc, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Genfit SA, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by GenKyoTex SA, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Gilead Sciences Inc, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Kowa Co Ltd, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by NGM Biopharmaceuticals Inc, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Novartis AG, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Tiziana Life Sciences Plc, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Virobay Inc, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Dormant Projects, H2 2019
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *